Virus-like particles (VLPs) are a class of subunit vaccines that differentiate themselves from
soluble recombinant antigens by stronger protective immunogenicity associated with the …

Subunit vaccines based on recombinant proteins can suffer from poor immunogenicity
owing to incorrect folding of the target protein or poor presentation to the immune system …

The nasal route for vaccination offers some important opportunities, especially for the
prophylaxis of respiratory diseases. Vaccination via the respiratory tract is reviewed and the …

Vaccines against viral disease have traditionally relied on attenuated virus strains or
inactivation of infectious virus. Subunit vaccines based on viral proteins expressed in …

Human papillomavirus-like particles (HPV VLPs) have shown considerable promise as a
parenteral vaccine for the prevention of cervical cancer and its precursor lesions. Parenteral …

Expression of the structural proteins L1 and L2 of the human papillomaviruses (HPV) is
tightly regulated. As a consequence, attempts to express these prime-candidate genes for …

Virus-like particles hold great promise for the development of effective and affordable
vaccines. Indeed, virus-like particles are suitable for presentation and efficient delivery of …

Cervical cancer remains a leading cause of death for women in the developing world, and
the treatment of preneoplastic cervical lesions is a considerable public-health burden in the …

Although many clinical trials on human papillomavirus (HPV) therapeutic vaccines have
been performed, clinical responses have not been consistent. We have addressed mucosal …

Papillomaviruses infect a wide variety of animals, including humans. The human
papillomavirus (HPV), in particular, is one of the most common causes of sexually …